Tag Archives: ZLAB

Zai Lab Ltd (ZLAB)

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

News about ZLAB

Week In Review: Human Gene Editing Scandal Revisited; Can China Biopharma Continue To Expand? News O
Industry Insights In a deeply researched Wall Street Journal article, Preetika Rana provides extraordinary depth into the story of Dr. Jiankui He, the man who announced last November he had used Crispr-Cas9 gene editing to alter human embryos in eigh...Read More>>>

Why Nike Rival Adidas (ADDYY) Looks Like A Strong Buy Stock Right Now
Shares of Adidas (ADDYY ) have cooled recently after an impressive two-year run. But the German sportswear giant looks like a strong buy at the moment as it continues to perform well against rival Nike (NKE ) .OverviewAdidas saw its second-quarter r...Read More>>>

Zai Lab (ZLAB) Downgraded by BidaskClub
BidaskClub downgraded shares of Zai Lab (NASDAQ:ZLAB) from a hold rating to a sell rating in a research note released on Friday morning. Other equities analysts have also recently issued reports about the company. Zacks Investment Research raised Zai...Read More>>>

Here's Why Zai Lab Limited Dropped Today
What happened Shares of Zai Lab (NASDAQ:ZLAB) are down 11% at 12:50 p.m. following the biotech's announcement after the bell yesterday that it priced its secondary offering of 7.5 million shares at $20 per share. So what Investors knew the secondary ...Read More>>>

Biotech Analysis Central Pharma News: Novartis' Positive News, Roche Unloads Drug, Zai Lab Suffers F
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Novartis Ends Up With Positive Trend In Late-Stage Breast Cancer Study News: Recently, Novartis (NYSE:NVS) announ...Read More>>>